

Prevalence of SARS-CoV-2 and co-occurrence/co-infection with malaria during the first wave of the pandemic (the Burkina Faso case)

1 **Diana López-Farfán¹, R. Serge Yerbanga², Marina Parres-Mercader¹, Manuela Torres-Puente³,**
2 **Inmaculada Gómez-Navarro³, Do Malick Soufiane Sanou², Adama Franck Yao², Jean Bosco**
3 **Ouédraogo², Iñaki Comas^{3,4}, Nerea Irigoyen⁴, Elena Gómez-Díaz^{1*}**

4 ¹Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones
5 Científicas (IPBLN-CSIC), Granada, Spain.

6 ²Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.

7 ³Institute of Biomedicine of Valencia (IBV-CSIC), Valencia, Spain.

8 ⁴CIBER in Epidemiology and Public Health, Madrid, Spain

9 ⁵Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK

10 *** Correspondence:**

11 Elena Gómez-Díaz

12 elena.gomez@csic.es

13 **Keywords: SARS-CoV-2, co-infection, malaria, Western Africa, Seroprevalence, genomic**
14 **surveillance. (Min.5-Max. 8)**

15 Number of words: 4.335

16 Number of figures: 2

17 Number of tables: 2

18 **Abstract**

19 Africa accounts for 1.5% of the global coronavirus disease 2019 (COVID-19) cases and 2.7% of deaths,
20 but this low incidence has been partly attributed to the limited testing capacity in most countries. In
21 addition, the population in many African countries is at high risk of infection with endemic infectious
22 diseases such as malaria. Our aim is to determine the prevalence and circulation of SARS-CoV-2
23 variants, and the frequency of co-infection with the malaria parasite. We conducted serological tests
24 and microscopy examinations on 998 volunteers of different ages and sexes in a random and stratified
25 population sample in Burkina-Faso. In addition, nasopharyngeal samples were taken for RT-qPCR of
26 SARS-COV-2 and for whole viral genome sequencing. Our results show a 3.2% and a 2.5% of SARS-
27 CoV-2 seroprevalence and PCR positivity; and 22% of malaria incidence, over the sampling period,
28 with marked differences linked to age. Importantly, we found 2 cases of confirmed co-infection and 8
29 cases of suspected co-infection mostly in children. Finally, we report the genome sequences of 13
30 SARS-CoV-2 isolates circulating in Burkina Faso at the time of analysis, assigned to lineages A.19,
31 A.21, B.1.1.404, B.1.1.118, B.1 and grouped into clades; 19B, 20A and 20B. This is the first
32 population-based study about SARS-CoV-2 and malaria in Burkina Faso during the first wave of the
33 pandemic, providing a relevant estimation of the real prevalence of SARS-CoV-2 and variants
34 circulating in this Sub-Saharan African country. Besides, it highlights the low frequency of co-infection
35 with malaria in African communities.

36 **1 Introduction**

37 To date, the SARS-CoV-2 coronavirus, responsible of the coronavirus disease 19 (COVID-19), has
38 caused more than 606 million cases and 6,5 million deaths worldwide, a small proportion of these (9,3
39 million cases [1.5%] and around 174,407 deaths [2.7%]) have occurred in Africa (data as of September
40 13th 2022, WHO¹). Despite their under-funded health systems, cases and deaths reported in Africa
41 appear low compared to other parts of the world. In addition, most of cases cluster in few Northern and
42 Southern countries (i.e. South Africa [4,01M cases], Morocco [1,26M cases] and Tunisia [1,14M
43 cases]), while data in most Western African countries is scarce or absent (i.e. the number of
44 accumulative cases considering all countries in Western Africa is ~936K). However, these estimations
45 should be considered with caution given the low number of tests conducted in most African countries
46 compared to data available for Europe (one or two orders of magnitude higher). A more proper effort
47 to estimate the real incidence is needed to make conclusions about the extent of this pandemic in the
48 African continent.

49 To prevent the emergence and spread of new variants across the world, sequencing of SARS-CoV-2
50 lineages circulating in Africa is critical (1). Indeed, the higher rates of COVID-19 testing and genomic
51 surveillance in the south of the continent have permitted the early identification of several variants of
52 concern (VOC) such as Beta (B.1.351) and Omicron (B.1.1.529); and different variants of interest
53 (VOI) such as C.1.1 (2,3). To date, most of the deposited sequences from Africa in the GISAID
54 database come from the South African region (47%), while sequences from Western African countries
55 only account for 17.6% (GISAID² as of 31 May 2022) (4). Such an uneven African genomic
56 surveillance holds a weakness in our global surveillance system and raises the concern of not leaving
57 Africa behind in the global pandemic response (1).

58 Besides the direct effects of COVID-19 in terms of cases and deaths, the pandemic has shown to have
59 important collateral effects on several other infectious diseases such as HIV/AIDS, tuberculosis and
60 malaria (5). According to the World Health Organization (WHO), half of all deaths in Africa are caused
61 by these three infectious diseases (~2.4 million people/year) compared to only 2% in Europe. The Sub-
62 Saharan Africa is one of the most affected regions with significant drops in notifications of all three
63 diseases. According to the latest WHO World malaria report³, 15 malaria endemic countries reported
64 more than 20% reduction in malaria testing and treatment between April and June of 2020³.

65 Malaria is a life-threatening disease caused by unicellular eukaryotic parasites of the genus
66 Plasmodium that are transmitted to humans through the bites of infected female Anopheles mosquitoes.
67 Sub-Saharan Africa carries a disproportionate portion of the global malaria burden. In 2020, the region
68 was home to 95% of malaria cases and deaths. Children below 5 years are the most vulnerable group
69 affected by malaria; accounting for 80% of all malaria deaths in the region³. At the beginning of the
70 COVID-19 pandemic, studies projected that malaria deaths could double in 2020 due to health service
71 disruptions (6). However, many countries took urgent actions to avoid the worst projections. In 2020,
72 there were an estimated 241 million cases of malaria and 627,000 deaths worldwide, this is 14 million
73 more cases and 69,000 more deaths than in 2019. Two-thirds of this increase have been associated to
74 disruption in malaria prevention campaigns, diagnosis and treatment during the first wave of the
75 pandemic³.

¹ <https://covid19.who.int/>

² <https://gisaid.org/submission-tracker-global/>

³ <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021>

76 Burkina Faso is a Western African country that confirmed its first community transmission cases of
77 SARS-CoV-2 on March 15, 2020. To date, this country has reported 21,128 total cases which is a very
78 low incidence compared with the 4M of total cases reported from South Africa, for example. Whether
79 this rate is representative of the real epidemiological situation of the country, or if it is due to
80 insufficient testing, remains and it will probably remain unanswered. On the other hand, malaria that
81 is endemic across the country, is a major health issue with a seasonal peak from June to October.
82 During the COVID-19 pandemic, malaria case incidence (cases per 1000 population at risk) increased
83 from 366.1 in 2019 to 389.9 in 2020⁴. The high malaria incidence in this country and the increase in
84 prevalence detected during the first wave of the COVID-19 pandemic raised the question about how
85 frequent has been SARS-CoV-2 and malaria co-infection.

86 In order to address this, 998 volunteers from different rural and urban areas in the south of Burkina
87 Faso were screened for malaria by microscopy, and for SARS-CoV-2 using rapid diagnostic serology
88 tests and RT-qPCR. In addition, PCR positive samples were whole-genome sequenced and analyzed
89 through comparative genomics and phylogenetics. We found a 3.2% seroprevalence and 2.5% of PCR
90 positivity for SARS-CoV-2 over the studied period. Although age groups mostly affected by each
91 disease do not overlap, 10 cases of SARS-CoV-2/malaria co-infection in younger age groups were
92 found. Finally, we reported 13 SARS-CoV-2 whole genomes circulating in Burkina Faso at the time
93 of sampling. Viral genomes clustered into 3 early clades (i.e. 19B, 20A and 20B) and lineages found
94 were A.19, A.21, B.1.1.404, B.1.1.118 and B.1.

95 Altogether, our data shed new light on the incidence of COVID-19 and the different SARS-CoV-2
96 circulating variants in a Western African country, and its co-occurrence with another endemic
97 infectious disease of utter importance such as malaria.

98 **2 Methods**

99 **Ethics**

100 This protocol was carried out by the Institut des Sciences et Techniques de Bobo-Dioulasso and was
101 approved by the Spanish National Research Council (CSIC), the Ethics Committee of Biomedical
102 Research in Andalusia (CCEIBA), and the Centre National de la Recherche Scientifique et
103 Technologique (CNRST) of Burkina-Faso. The protocol is in conformity with the declaration of
104 Helsinki and all international regulations about the ethical principles in biomedical research involving
105 human subjects. SARS-CoV-2 seropositive and malaria positive individuals were provided with
106 treatment and assisted by medical professionals. During the screening, local authorities, school
107 directors and families of volunteers were informed about the objectives of the study and protocols
108 performed. As the study involved children, a signed declaration of conformity for the participation in
109 the study was obtained from their parents and/or legal representatives.

110 **Study design**

111 The study was conducted in 11 villages from different rural and urban areas in the south of Burkina
112 Faso (**Supplementary Figure 1**). From August to November 2020, a total of 998 asymptomatic
113 volunteers were enrolled. Demographic and clinical information collected included age, sex and
114 temperature. For each participating subject, two drops of blood were obtained by capillary puncture of
115 the fingertip. This blood was used for malaria detection by microscopy, and for COVID-19 serology

⁴ <https://data.worldbank.org/indicator/SH.MLR.INCD.P3?locations=BF>, accessed on 27 April 2022

116 testing using a point of care rapid test (INgezim COVID-19 CROM Easy). When there was consent,
117 nasopharyngeal samples were also collected in AVL buffer (Qiagen) for molecular testing of SARS-
118 CoV-2 using RT-qPCR.

119 **SARS-CoV-2 diagnosis**

120 Detection of anti-SARS-CoV-2 antibodies was performed on volunteers' capillary blood using the
121 INgezim COVID-19 CROM Easy kit (Gold Standard Diagnostics), following manufacturer's
122 instructions. This serology-based finger-prick test is based on a dual-recognition
123 immunochromatographic assay that determines the presence of total antibodies (IgG, IgA, and IgM)
124 specific to SARS-CoV-2 in a single blood sample by using the nucleoprotein (N protein) as antigen.
125 The manufacturer reported specificity of 99.3% and sensitivity of 94.5%. No cross-reactivity with other
126 coronaviruses or agents related to human respiratory illnesses have been reported. In this study, we
127 estimated seroprevalence as the proportion of individuals who had a positive result in the point-of-care
128 test after 10 minutes.

129 Nasopharyngeal samples were taken using a sterile swab. The swab was immediately placed in a pre-
130 filled tube containing 0.5 mL of inactivating lysis buffer (AVL, Qiagen). Samples were stored at 4°C
131 for 24h and at -20°C for prolonged storage for subsequent analysis. Molecular detection of SARS-
132 CoV-2 by RT-qPCR on seropositive volunteers was carried out in the Institut de Recherche en Sciences
133 de la Santé/ Direction Régionale de l'Ouest (IRSS DRO) of Burkina Faso using the FastPlexTriplex
134 SARS-CoV-2 detection kit (gene target identified: ORF1ab, N and the human RNase P as control)
135 (PreciGenome, LLC).

136 Swab samples of seronegative volunteers were stored at -80°C and processed in the Institute of
137 Parasitology and Biomedicine Lopez-Neyra (IPBLN) as follows: RNA was extracted from 140 µL of
138 pooled swab samples using the QIAamp viral RNA extraction kit (Qiagen). A pool size of five samples
139 was used in the villages with seropositive subjects (Bobo-Dioulasso and Dandé), whereas samples from
140 villages with negative seroprevalence were processed in pools of 10 samples. RT-qPCR analysis was
141 performed using the one step Direct SARS-CoV-2 Realtime PCR Kit (Vircell S.L) following the
142 manufacturer's instructions. Targets identified with this kit are N, E and hRNase P genes. RT-qPCR
143 was performed in 20 µL final volume reactions (5 µL of RNA sample) using a CFX96 Real-Time PCR
144 Detection System (Bio-Rad, Hercules, CA, USA). Cycle threshold (Ct) values were analyzed using the
145 BIORAD CFX manager software. Samples of positive pools were extracted individually and retested
146 by RT-qPCR. Samples were considered positive when the N and E target genes had a Ct < 40. Positive
147 and negative controls were included in all experiments.

148 **Whole Genome Sequencing and Phylogenetic Analysis**

149 RNA from SARS-CoV-2 positive samples with a Ct value ≤ 35 was sent to sequencing to the Institute
150 of Biomedicine of Valencia (IBV-CSIC). RNA was retrotranscribed into cDNA and SARS-CoV-2
151 complete genome amplification was performed in two multiplex PCR, accordingly to openly available
152 protocol developed by the ARTIC network⁵ using the V4.1 multiplex primers scheme (artic-network
153 n.d.). Two resulting amplicon pools were combined and used for library preparation. Genomic libraries
154 were constructed with the Nextera DNA Flex Sample Preparation kit (Illumina Inc., San Diego, CA)
155 according to the manufacturer's protocol with 5 cycles for indexing PCR. Whole genome sequencing
156 was carried out in a MiSeq platform (2×150 cycles paired-end run; Illumina). Sequences obtained went

⁵ https://www.protocols.io/view/ncov-2019-sequencing-protocol-bp2l6n26rgqe/v1?version_warning=no

157 through an open source bioinformatic pipeline based on IVAR⁶ (7). The different steps of the pipeline
158 are as follows: 1) removal of human reads with Kraken (8); 2) filtering of the fastq files using fastp v
159 0.20.1 (9) (arguments: --cut tail, --cut-window-size, --cut-mean-quality, -max_len1, -max_len2); 3)
160 mapping and variant calling using IVAR v 1.2; and 4) quality control assessment with MultiQC (10).
161 Consensus sequences generated by this pipeline were aligned against the SARS-CoV-2 reference
162 sequence (11) with MAFFT (12). Problematic positions were masked using the mask_alignment.py
163 script from the repository maintained by Rob Lanfear⁷. Lineages and clade nomenclature were assigned
164 using Pangolin (13) and Nexclade online tool (14). Phylogenetic tree was generated with Nextclade
165 v2.5.0⁸, the tree was downloaded in JSON format and visualized using Auspice v2.37.3 online tool⁹
166 (15,16).

167 **Malaria diagnosis**

168 Malaria prevalence was estimated in the same population sample of 998 volunteers simultaneously to
169 SARS-CoV-2 detection. Detection of malaria was performed by microscopic examination of blood
170 thick smears that were prepared following standard methods (17). Thick smears were screened for the
171 presence of *Plasmodium falciparum* asexual and gametocyte stages in the blood.

172 **Statistical analysis**

173 We tested the association between variables with the Wilcoxon Sum Rank tests (for continuous
174 quantitative variables) and the Kruskal-Wallis chi-squared test.

175 **3 Results and Discussion**

176 COVID-19 transmission in Africa has been marked by relatively fewer infections, mostly
177 asymptomatic, and lower death rate compared to developed countries. A younger population structure
178 and a variety of socio-ecological factors (i.e. warm weather, low population density and mobility and
179 trained immunity by previous high burden infectious diseases), as well as early public health measures
180 taken by governments (i.e. early lockdown sub-Saharan countries) (18), have been suggested to explain
181 such lower incidence (19). Surprisingly, the pandemic has been more pronounced in a few countries
182 (e.g. South Africa, Morocco and Tunisia) suggesting country-specific drivers of SARS-CoV-2 spread
183 and morbidity, but this could also be largely explained by a low and unequal testing capacity. Reported
184 cases of COVID-19 are dissimilar between countries like South Africa (4,01 million cases and 102,129
185 deaths), Kenia (338,301 cases and 5,674 deaths) or Ethiopia (493,353 cases and 7,572 deaths). Testing
186 also differs greatly, with 50,000 tests/day in South Africa versus 5,000 tests/day in Kenia or Ethiopia.
187 In Burkina Faso, with a population of 20,903,278, only 21,128 cases and 387 deaths have been reported
188 (as of September 13th 2022, WHO¹). However, no data about the testing effort in Burkina Faso are
189 available for comparison.

190 At the beginning of the pandemic, serological surveillance was used as a prospective tool to define the
191 cumulative incidence of COVID-19, particularly in the presence of asymptomatic or mild infections
192 (20). At present, seven countries in Western Africa, four countries in Eastern Africa and four countries

⁶ <https://gitlab.com/fisabio-ngs/sars-cov2-mapping>

⁷ <https://zenodo.org/record/4069557#.X37nuXUzaWg>

⁸ <https://clades.nextstrain.org> (accessed on 13 September 2022)

⁹ <https://auspice.us/>

193 in Central Africa have conducted seroprevalence studies that are published or available as preprint
194 (**Supplementary Table 1**). Serological surveys in African countries show highly heterogeneous results
195 with SARS-CoV-2 seroprevalence ranging from 0.9% to 45% during 2020 (**Supplementary Table 1**).
196 To our knowledge, no data have been reported from Burkina Faso for any period.

197 In this study, we report the results of a population-based and stratified survey involving a total of 998
198 volunteers that were recruited during a period of 3 months in 2020 (August 22nd to November 19th).
199 The sampling was conducted in 11 villages from different rural and urban areas in the south of Burkina
200 Faso (**Supplementary Figure 1**). 55% of the participants (549 out of 998) were female, and 45% (449
201 out of 998) were male. The samples were distributed equally into four age groups: (A) 5-12 years
202 (25.2%); (B) 13-20 years (24.9%); (C) 21-40 years (25.2%); and (D) >40 years (24.7%). Importantly,
203 all the participants were asymptomatic. The distribution of positive cases by age and gender classes is
204 detailed in **Table 1**.

205 A total of 32 individuals out of 998 tested positive for SARS-CoV-2 total antibodies (IgG/A/M),
206 resulting in an overall seroprevalence rate of 3.2% (95% CI 2.1–4.3). However, most of seropositives
207 came from the urban city of Bobo-Dioulasso where local seroprevalence was of 4.96% at that time. A
208 higher seroprevalence in urban areas in Africa has been reported previously (21–24). Apart from urban
209 vs. rural differences, we report significant differences between age groups in SARS-CoV-2
210 seropositivity (Kruskal-Wallis chi-squared=16.285, df=3, p-value < 0.001). The highest
211 seroprevalence was in the group age of >40 years (6.9% [95% CI 3.7–10.1]), followed by teenagers
212 aged 13-20 years (2.8% [95% CI 0.7–4.9]) and children aged 5–12 years (2.4% [95% CI 0.5–4.3]),
213 whereas the lowest seroprevalence was observed in the group of 21-40 years (0.8% [95% CI 0–1.9]).
214 (**Figure 1A, Table 1**). However, there were no significant differences in SARS-CoV-2 seroprevalence
215 between female and male individuals (Wilcoxon rank sum test $W = 15690$, p-value = 0.78)
216 (**Supplementary Figure 2**), which agrees with other population-wide seroprevalence surveys in Sub-
217 Saharan Africa (22,25,26). Finally, we also observed that SARS-CoV-2 seroprevalence varied
218 markedly with time with a significant increase in the incidence with a maximum of ~5.5% in November
219 2020 (**Supplementary Figure 3**). This increase in infection rate agrees with previously published
220 reports from the African CDC and WHO¹ that observed a gradually increase in cases since September
221 2020.

222 Furthermore, seroprevalence estimates for SARS-CoV-2 obtained in this study are also comparable
223 with results reported in other African countries during 2020 (although sample period and the testing
224 effort might be different) (**Supplementary Table 1**). For example, in a serosurvey of asymptomatic
225 people conducted in May 2020 in Addis Ababa (Ethiopia), 3.0% tested positive for SARS-CoV-2 IgG
226 (27). Similarly, a seroprevalence study of 3,098 Kenyan blood donors sampled between April-June
227 2020 reported a national seroprevalence of 4.3%, with some urban regions reaching around 8% (e.g.
228 Nairobi and Mombasa) (21). Another study in Ethiopia during July 2020 in 14 urban areas found a
229 seroprevalence of 3.5% from 16,932 samples (22).

230 The 32 SARS-CoV-2 seropositive individuals were subjected to RT-qPCR. SARS-CoV-2 active
231 infection was confirmed in 7 samples (seropositive/PCR positive). Due to the low sensitivity of rapid
232 antibody tests to detect early infections, all the seronegative samples were also analyzed by RT-qPCR.
233 Swab samples were first processed in pools, and then, positive pools were processed individually.
234 Pooled testing is a useful approach to reduce time, cost and increase testing capacity in areas with low
235 prevalence of COVID-19. This PCR pooling works with maximum efficiency with a prevalence <3%
236 and a pool size <10 (28,29). First, we tested the sensitivity of our ‘pool-test’ in groups of five (one
237 positive sample diluted in four negative ones) and ten (one positive sample diluted in nine negative

238 ones) samples (**Supplementary Table 2**). With these results, we decided to group samples in pools of
239 five in areas with seropositive subjects (i.e. Bobo-Dioulasso and Dandé); whereas samples from areas
240 with zero seroprevalence, pools of 10 swabs were processed instead. RNA was extracted from pooled
241 swab samples and RT-PCR was performed. Then, samples in positive pools were extracted and tested
242 individually. With this procedure, we found 17 additional SARS-CoV-2 positive samples by RT-qPCR,
243 most of them from the urban locality of Bobo-Dioulasso (**Table 1, Figure 1B**). In concordance with
244 serological tests, there were not significant differences in SARS-CoV-2 PCR positivity between
245 females and males (Wilcoxon rank sum test $W = 125348$, p -value = 0.08114) (**Supplementary Figure**
246 **2**). However, there were significant differences between age groups (Kruskal-Wallis chi-squared =
247 20.155, $df = 3$, p -value < 0.001) with the highest prevalence in the age group of >40 years decreasing
248 with age. The lowest prevalence was observed in children between 5–12 years (**Figure 1A, Table 1**).

249 19 out of 24 SARS-CoV-2 PCR positive samples had a Ct value ≤ 35 and they were processed for
250 whole-genome sequencing. After genome assembly and quality control processes, good quality
251 genomes were obtained from 13 samples. To assign the sequences to lineages and clades, we used the
252 dynamic lineage classification method called Phylogenetic Assignment of Named Global Outbreak
253 Lineages (PANGOLIN) (13) and the sequence analysis web tool, Nextclade (14). Phylogenetic
254 analysis showed that our SARS-CoV-2 genomes clustered into three clades: 19B, 20A and 20B (**Table**
255 **2, Figure 2**). Most of the samples belong to clade 19B, this one along with 19A were the clades that
256 emerged in Wuhan in late 2019 and dominated the early outbreak. Clade 20A emerged from 19A and
257 dominated the European outbreak in March 2020, and 20B is a sub-clade of 20A (30). Lineages found
258 were A.19, A.21, B.1.1.404, B.1.1.118 and B.1. The distribution and description of these lineages¹⁰ are
259 summarized in **Supplementary Table 3**. Lineages A.19, A.21 and B.1.1.404 were common in Burkina
260 Faso at the time of analysis, and importantly, were described there for the first time¹⁰. However,
261 lineages B.1.1.118 and B.1 were not common in Burkina Faso nor even in Africa at that time¹⁰. As
262 these lineages presented a worldwide distribution, they probably correspond to imported lineages.
263 Indeed, B.1 was reported in Morocco, Saudi Arabia, Spain, France and Brazil on February 2020¹¹. A
264 genomic study of SARS-CoV-2 conducted in Ghana with samples from March 12 to April 1 2020 and
265 the end of May 2020, reports the same clades that we found circulating in Burkina Faso from August
266 to November 2020, moreover they also report the lineage B.1 (31). Although little divergence was
267 observed (**Figure 2**) as sequences comes from early days in the pandemic, we detected a common spike
268 mutation in most of the Burkina Faso genomes, D614G mutation (**Table 2**). A SARS-CoV-2 variant
269 carrying this mutation became dominant during the early days of the pandemic at global level and had
270 a presumed fitness advantage (32). The D614G mutation was also dominant in Guinea genomes (31)
271 and north-middle African genomes (33).

272 In order to estimate the frequency of SARS-CoV-2/malaria co-infection for the same period and
273 subjects, malaria was screened by microscopy. 219 individuals out of 998 tested positive for malaria
274 (22% CI 19.4–24.5). Like in the case of SARS-CoV-2, there were significant differences in malaria
275 prevalence between age groups (Kruskal-Wallis chi-squared = 132.18, $df = 3$, p -value < 0.001), but in
276 this case, malaria was mostly detected in children below 12 years old (42.2%; 95% CI 36.1–48.4)
277 (**Figure 1; Table 1**). In addition, a small sex difference was observed with a higher prevalence in male
278 subjects ($W = 92508$, p -value < 0.05) (**Supplementary Figure 2**). Similar to the temporal trend
279 observed for SARS-CoV-2, malaria cases also showed a significant increase from 5.26% at the
280 beginning of the study to 29.2% at the end of the sampled period (**Supplementary Figure 3**). This

¹⁰ https://cov-lineages.org/lineage_list.html

¹¹ <https://gisaid.org/phylogenomics/global/nextstrain/>

281 could suggest an impact in malaria control due to the pandemic. Indeed, according to official reports,
282 the incidence of malaria in Burkina Faso (cases per 1000 population at risk) increased from 366.1 in
283 2019 to 389.9 in 2020¹². Of the 7 SARS-CoV-2 seropositive/PCR positive samples, none of them were
284 co-infected with malaria. Whereas of the 17 seronegative/PCR positive samples, two co-infections with
285 malaria were reported (**Table 1, Figure 1B**). Finally, of the remaining 25 seropositive/PCR negative
286 subjects, 8 were positive for malaria (**Table 1, Figure 1B**). Since the serology test measures total
287 antibodies (IgG/A/M) for SARS-CoV-2, it cannot differentiate recent or past infections, therefore, we
288 cannot rule out whether these data correspond to a co-infection or a sequential infection.

289 To summarize, we found 2 cases of confirmed SARS-CoV-2 (PCR positive) co-infection with malaria
290 and 8 cases of suspected co-infection (seropositive/PCR negative). Of them, eight were children and
291 teenagers below 14 years and two were adults of >40 years (**Table 1**). There were no significant
292 differences in coinfection frequency between females and males (6 males, 4 females). Only one of the
293 two PCR positive co-infected samples was suitable for sequencing (Ct < 35) and the lineage was A.21.

294 Similar low frequency for SARS-CoV-2 and malaria co-infections found in our study (1%) has been
295 also reported in other studies (34–38) (**Supplementary Table 4**). A systematic review of COVID-19
296 and malaria coinfection studies has estimated 11% of pooled prevalence (data of 5 studies) with a high
297 degree of heterogeneity (39). However, it is important to note that these studies examined symptomatic
298 patients at the hospital and our study tested stratified asymptomatic people randomly. A recent study
299 reported a higher prevalence of co-infection (12%) with highest prevalence in the age group of 0–20
300 years (22%) and above 60 years (20%), in this case malaria infection was evaluated in a cohort of
301 hospitalized patients in Uganda with SARS-CoV-2 PCR-confirmed infection (40). As for the
302 symptomatology of co-infections, preliminary data suggest that patients with SARS-CoV-2 and
303 malaria did not seem to have a worst disease outcome but previous malaria exposure seems to be related
304 to less frequency of severe COVID-19 (40). Another study reports that patients co-infected with
305 malaria had significantly faster recovery compared to those not co-infected (38). One limitation of our
306 study to analyze and draw conclusions about clinical outcomes of the co-infections is that all volunteers
307 were asymptomatic. In addition, the low frequency of SARS-CoV-2 and malaria parasite single
308 infections in the population (the small sample size of volunteers that were positive for either disease),
309 reduces the probability of find them together.

310 It has been suggested that the low incidence and mortality of COVID-19 in malaria endemic regions
311 could be related to cross-immunity and common immunodominant epitopes between malaria and
312 SARS-CoV-2 (40–43). In-silico analysis have identified potential shared targets for immune response
313 between SARS-CoV-2 and *Plasmodium falciparum* proteins which could generate cross-reactivity
314 through HLA and CD8+ T-cell activation (42). Moreover, tuberculosis and malaria prevalence had
315 been significantly associated with reduced COVID-19 mortality (43). Previous studies have also
316 indicated that malaria-induced immunomodulation could be protective against respiratory viruses,
317 reducing pulmonary inflammatory response inflammation (44,45). Alternatively, the higher burden of
318 infectious diseases in sub-Saharan Africa has been suggested to mediate the asymptomatic SARS-
319 CoV-2 infections by induction of immunological tolerance or trained immunity to other infections such
320 as tuberculosis, other human coronaviruses and even Bacillus Calmette-Guérin (BCG) vaccination
321 (19,43). In addition, other studies have reported that bacterial, fungal and viral co-infections with
322 SARS-CoV-2 are also uncommon, however when present, they may cause a worse outcome (46–48).
323 In the case of coinfections with HIV, the prevalence seems higher (26,6%) and HIV subjects showed

¹² <https://data.worldbank.org/indicator/SH.MLR.INCD.P3?locations=BF>

324 an increased risk of hospital admission for COVID-19 (49). However, the studies are still preliminary
325 and further research is needed to test these hypotheses. Therefore, additional prospective studies are
326 required to establish a cause-effect relationship between the SARS-CoV-2 disease outcome and co-
327 infection with other circulating pathogens. These should include more patients, control groups, clinical
328 and immunological information, tracing on SARS-CoV-2 severity when co-occurrence with other
329 prevalent infectious diseases.

330 **4 Conclusions**

331 To our knowledge, this is the first population-based SARS-CoV-2 prevalence study performed in
332 Burkina-Faso during the first wave of the COVID-19 pandemic. In addition, this is also one of the few
333 studies that examines the co-occurrence of SARS-CoV-2 infection with the malaria parasite in an
334 asymptomatic population.

335 The findings from this seroprevalence study for SARS-CoV-2 indicate that the prevalence of antibodies
336 against the new coronavirus was around 3% in Burkina Faso at the time of analysis, with large
337 differences in prevalence at local level and between various age classes. This supports the hypothesis
338 that Africa had one of the lowest coronavirus case rates and that would not be due, at least entirely, to
339 a lower testing capacity. Another important finding of our study is the low frequency of co-infection
340 with malaria among the sampled population (1.0%). Of these, 8 out of the 10 cases reported were in
341 children (4) or teenagers (4), and 2 cases in adults of >40 years.

342 Finally, the whole genome sequencing analysis revealed that the circulating lineages found in Burkina
343 Faso during the first wave of the pandemic were early clades derived from the Wuhan strain. Most of
344 the lineages reported have been previously described in Burkina Faso or the neighbour countries.
345 However, we also identified two less frequent lineages that were probably imported to Burkina-Faso
346 from USA or Europe. We believe that data presented in this study help to fill the gap of the SARS-
347 CoV-2 epidemiological situation in sub-Saharan Africa, where interactions with endemic infectious
348 diseases are common.

349 **5 Conflict of Interest**

350 *The authors declare that the research was conducted in the absence of any commercial or financial*
351 *relationships that could be construed as a potential conflict of interest.*

352 **6 Author Contributions**

353 Conceptualization was the responsibility of EG-D that also supervised the project with NI . RSY and
354 JBO provided infrastructure and organized fieldwork activities in Burkina Faso. SRY, DMSS, AFY
355 performed data collection. DL-F and MP-M performed RT-qPCR assays. IC, IG-M and MT-P
356 conducted whole genome sequencing and phylogenetic analysis. DL-F and EG-D analysed the data
357 and wrote the manuscript. NI, SRY and IC reviewed the manuscript. All authors read and approved the
358 final manuscript.

359 **7 Funding**

360 This research work received funding from by the European Commission–NextGenerationEU
361 (Regulation EU 2020/2094) and grant: 202020E159, through CSIC’s Global Health Platform (PTI
362 Salud Global).

363 **8 Acknowledgments**

364 We would like to thank all volunteers who participated in this study, as well as the local authorities
365 and communities in Burkina Faso for their support. We also thank the IPBLN, IRSS and IBV core
366 facilities for their support to project activities.

367 **9 References**

- 368 1. Wilkinson E, Giovanetti M, Tegally H, San JE, Lessells R, Cuadros D, et al. A year of genomic
369 surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. *Science* (80-).
370 2021;374(6566):423–31.
- 371 2. Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529) - variant of concern - molecular
372 profile and epidemiology: A mini review. *Eur Rev Med Pharmacol Sci*. 2021;25(24):8019–22.
- 373 3. Tegally H, Wilkinson E, Lessells RJ, Giandhari J, Pillay S, Msomi N, et al. Sixteen novel
374 lineages of SARS-CoV-2 in South Africa. *Nat Med* [Internet]. 2021;27(3):440–6. Available
375 from: <http://dx.doi.org/10.1038/s41591-021-01255-3>
- 376 4. Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. GISAID’s Role in Pandemic
377 Response. *China CDC Wkly* [Internet]. 2021 Dec 12 [cited 2022 Sep 16];3(49):1049. Available
378 from: [/pmc/articles/PMC8668406/](https://pubmed.ncbi.nlm.nih.gov/38668406/)
- 379 5. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential
380 impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and
381 middle-income countries: a modelling study. *Lancet Glob Heal*. 2020 Sep 1;8(9):e1132–41.
- 382 6. Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P, et al. The
383 potential public health consequences of COVID-19 on malaria in Africa. *Nat Med* [Internet].
384 2020;26(9):1411–6. Available from: <http://dx.doi.org/10.1038/s41591-020-1025-y>
- 385 7. Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, et al. An
386 amplicon-based sequencing framework for accurately measuring intrahost virus diversity using
387 PrimalSeq and iVar. *Genome Biol* [Internet]. 2019 Jan 8 [cited 2022 Sep 16];20(1):1–19.
388 Available from: [https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1618-](https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1618-7)
389 [7](https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1618-7)
- 390 8. Wood DE, Salzberg SL. Kraken: Ultrafast metagenomic sequence classification using exact
391 alignments. *Genome Biol* [Internet]. 2014 Mar 3 [cited 2022 Sep 16];15(3):1–12. Available
392 from: <https://genomebiology.biomedcentral.com/articles/10.1186/gb-2014-15-3-r46>
- 393 9. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
394 *Bioinformatics* [Internet]. 2018 Sep 9 [cited 2022 Sep 16];34(17):i884. Available from:
395 [/pmc/articles/PMC6129281/](https://pubmed.ncbi.nlm.nih.gov/3122281/)
- 396 10. Ewels P, Magnusson M, Lundin S, Källner M. MultiQC: summarize analysis results for multiple
397 tools and samples in a single report. *Bioinformatics* [Internet]. 2016 Oct 1 [cited 2022 Sep
398 16];32(19):3047–8. Available from:
399 <https://academic.oup.com/bioinformatics/article/32/19/3047/2196507>

- 400 11. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with
401 human respiratory disease in China. *Nat* 2020 5797798 [Internet]. 2020 Feb 3 [cited 2022 Sep
402 16];579(7798):265–9. Available from: <https://www.nature.com/articles/s41586-020-2008-3>
- 403 12. Katoh K, Standley DM. MAFFT Multiple Sequence Alignment Software Version 7:
404 Improvements in Performance and Usability. *Mol Biol Evol* [Internet]. 2013 Apr 1 [cited 2022
405 Sep 16];30(4):772–80. Available from:
406 <https://academic.oup.com/mbe/article/30/4/772/1073398>
- 407 13. O’Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment of
408 epidemiological lineages in an emerging pandemic using the pangolin tool. *Virus Evol*
409 [Internet]. 2021 [cited 2022 Sep 16];7(2). Available from: </pmc/articles/PMC8344591/>
- 410 14. Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment, mutation
411 calling and quality control for viral genomes. *J Open Source Softw* [Internet]. 2021 Nov 30
412 [cited 2022 Sep 16];6(67):3773. Available from:
413 <https://joss.theoj.org/papers/10.21105/joss.03773>
- 414 15. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. NextStrain: Real-time
415 tracking of pathogen evolution. *Bioinformatics*. 2018 Dec 1;34(23):4121–3.
- 416 16. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis.
417 *Virus Evol* [Internet]. 2018 Jan 1 [cited 2022 Sep 16];4(1). Available from:
418 </pmc/articles/PMC5758920/>
- 419 17. WHO. Malaria Microscopy Quality Assurance Manual. 2009;
- 420 18. Haider N, Osman AY, Gadzekpo A, Akipede GO, Asogun D, Ansumana R, et al. Lockdown
421 measures in response to COVID-19 in nine sub-Saharan African countries. *BMJ Glob Heal*.
422 2020;5(10):1–10.
- 423 19. Kusi KA, Frimpong A, Partey FD, Lamptey H, Amoah LE, Ofori MF. High infectious disease
424 burden as a basis for the observed high frequency of asymptomatic SARS-CoV-2 infections in
425 sub-Saharan Africa. *AAS Open Res*. 2021;4(May):2.
- 426 20. Wu X, Fu B, Chen L, Feng Y. Serological tests facilitate identification of asymptomatic SARS-
427 CoV-2 infection in Wuhan, China. *J Med Virol* [Internet]. 2020 Oct 1 [cited 2022 Sep
428 16];92(10):1795–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/32311142/>
- 429 21. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of
430 anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. *Science* (80-). 2021;371(6524):79–
431 82.
- 432 22. Tadesse EB, Endris AA, Solomon H, Alayu M, Kebede A, Eshetu K, et al. Seroprevalence and
433 risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional
434 evaluation during July 2020. *Int J Infect Dis* [Internet]. 2021;111:179–85. Available from:
435 <https://doi.org/10.1016/j.ijid.2021.08.028>
- 436 23. Barrie MB, Lakoh S, Kelly JD, Kanu JS, Squire JS, Koroma Z, et al. SARS-CoV-2 antibody
437 prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-

- 438 stratified serosurvey. *BMJ Glob Heal* [Internet]. 2021;6:7271. Available from:
439 <http://gh.bmj.com/>
- 440 24. Abdella S, Riou S, Tessema M, Assefa A, Seifu A, Blachman A, et al. Prevalence of SARS-
441 CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread
442 during the first wave of the pandemic. *EClinicalMedicine* [Internet]. 2021 May 1 [cited 2022
443 Jul 5];35. Available from: <https://pubmed.ncbi.nlm.nih.gov/34124630/>
- 444 25. Wiens KE, Mawien PN, Rumunu J, Slater D, Jones FK, Moheed S, et al. Seroprevalence of
445 severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020. *Emerg Infect
446 Dis*. 2021;27(6):1598–606.
- 447 26. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence of
448 SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey.
449 *Lancet Glob Heal* [Internet]. 2021;9(6):e773–81. Available from:
450 [http://dx.doi.org/10.1016/S2214-109X\(21\)00053-X](http://dx.doi.org/10.1016/S2214-109X(21)00053-X)
- 451 27. Kempen JH, Abashawl A, Suga HK, Difabachew MN, Kempen CJ, Debele MT, et al. SARS-
452 CoV-2 serosurvey in Addis Ababa, Ethiopia. *Am J Trop Med Hyg*. 2020;103(5):2022–3.
- 453 28. Daniel EA, Esakialraj L BH, S A, Muthuramalingam K, Karunaianantham R, Karunakaran LP,
454 et al. Pooled Testing Strategies for SARS-CoV-2 diagnosis: A comprehensive review. *Diagn
455 Microbiol Infect Dis* [Internet]. 2021 Oct 1 [cited 2022 Sep 16];101(2). Available from:
456 <https://pubmed.ncbi.nlm.nih.gov/34175613/>
- 457 29. de Salazar A, Aguilera A, Trastoy R, Fuentes A, Alados JC, Causse M, et al. Sample pooling
458 for SARS-CoV-2 RT-PCR screening. *Clin Microbiol Infect* [Internet]. 2020 Dec 1 [cited 2022
459 Sep 16];26(12):1687.e1-1687.e5. Available from: <https://pubmed.ncbi.nlm.nih.gov/32919074/>
- 460 30. Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, et al.
461 Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region,
462 January to June 2020. *Eurosurveillance* [Internet]. 2020 Aug 13 [cited 2022 Sep
463 14];25(32):2001410. Available from: [https://www.eurosurveillance.org/content/10.2807/1560-
464 7917.ES.2020.25.32.2001410](https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.32.2001410)
- 465 31. Ngoi JM, Quashie PK, Morang’a CM, Bonney JHK, Amuzu DSY, Kumordjie S, et al. Genomic
466 analysis of SARS-CoV-2 reveals local viral evolution in Ghana. *Exp Biol Med*.
467 2021;246(8):960–70.
- 468 32. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes
469 in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
470 *Cell*. 2020 Aug 20;182(4):812-827.e19.
- 471 33. Sallam M, Ababneh NA, Dababseh D, Bakri FG, Mahafzah A. Temporal increase in D614G
472 mutation of SARS-CoV-2 in the Middle East and North Africa. *Heliyon*. 2021 Jan
473 1;7(1):e06035.
- 474 34. Bakamutumaho B, Cummings MJ, Owor N, Kayiwa J, Namulondo J, Byaruhanga T, et al.
475 Severe COVID-19 in Uganda across two epidemic phases: A prospective cohort study. *Am J
476 Trop Med Hyg*. 2021;105(3):740–4.

- 477 35. Morton B, Barnes KG, Anscombe C, Jere K, Matambo P, Mandolo J, et al. Distinct clinical and
478 immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan
479 Africa. *Nat Commun.* 2021;12(1).
- 480 36. Matangila JR, Nyembu RK, Telo GM, Ngoy CD, Sakobo TM, Massolo JM, et al. Clinical
481 characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in
482 Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study. *PLoS One*
483 [Internet]. 2020;15(12 December):1–15. Available from:
484 <http://dx.doi.org/10.1371/journal.pone.0244272>
- 485 37. Amoo OS, Aina OO, Okwurawe AP, Onwuamah CK, Shaibu JO, Ige F, et al. COVID-19
486 Spread Patterns Is Unrelated to Malaria Co-Infections in Lagos, Nigeria. *Adv Infect Dis.*
487 2020;10(05):200–15.
- 488 38. Mahajan NN, Gajbhiye RK, Bahirat S, Lokhande PD, Mathe A, Rathi S, et al. Co-infection of
489 malaria and early clearance of SARS-CoV-2 in healthcare workers. *J Med Virol.*
490 2021;93(4):2431–8.
- 491 39. Wilairatana P, Masangkay FR, Kotepui KU, Milanez GDJ, Kotepui M. Prevalence and
492 characteristics of malaria among covid-19 individuals: A systematic review, meta-analysis, and
493 analysis of case reports. *PLoS Negl Trop Dis* [Internet]. 2021;15(10):1–18. Available from:
494 <http://dx.doi.org/10.1371/journal.pntd.0009766>
- 495 40. Achan J, Serwanga A, Wanzira H, Kyagulanyi T, Nuwa A, Magumba G, et al. Current malaria
496 infection, previous malaria exposure, and clinical profiles and outcomes of COVID-19 in a
497 setting of high malaria transmission: an exploratory cohort study in Uganda. *The Lancet*
498 *Microbe* [Internet]. 2022;3(1):e62–71. Available from: [http://dx.doi.org/10.1016/S2666-](http://dx.doi.org/10.1016/S2666-5247(21)00240-8)
499 [5247\(21\)00240-8](http://dx.doi.org/10.1016/S2666-5247(21)00240-8)
- 500 41. Osei SA, Biney RP, Anning AS, Nortey LN, Ghartey-Kwansah G. Low incidence of COVID-
501 19 case severity and mortality in Africa; Could malaria co-infection provide the missing link?
502 *BMC Infect Dis* [Internet]. 2022;22(1):1–11. Available from: [https://doi.org/10.1186/s12879-](https://doi.org/10.1186/s12879-022-07064-4)
503 [022-07064-4](https://doi.org/10.1186/s12879-022-07064-4)
- 504 42. Iesa MAM, Osman MEM, Hassan MA, Dirar AIA, Abuzeid N, Mancuso JJ, et al. SARS-CoV-
505 2 and *Plasmodium falciparum* common immunodominant regions may explain low COVID-19
506 incidence in the malaria-endemic belt. *New microbes new Infect* [Internet]. 2020 Nov 1 [cited
507 2022 Jul 7];38. Available from: <https://pubmed.ncbi.nlm.nih.gov/33230417/>
- 508 43. Raham TF. Influence of malaria endemicity and tuberculosis prevalence on COVID-19
509 mortality. *Public Health* [Internet]. 2021;194:33–5. Available from:
510 <https://doi.org/10.1016/j.puhe.2021.02.018>
- 511 44. Edwards CL, Zhang V, Werder RB, Best SE, Sebina I, James KR, et al. Coinfection with Blood-
512 Stage *Plasmodium* Promotes Systemic Type I Interferon Production during Pneumovirus
513 Infection but Impairs Inflammation and Viral Control in the Lung. *Clin Vaccine Immunol*
514 [Internet]. 2015 May 1 [cited 2022 Jul 7];22(5):477–83. Available from:
515 <https://pubmed.ncbi.nlm.nih.gov/25716232/>
- 516 45. Thompson MG, Breiman RF, Hamel MJ, Desai M, Emukule G, Khagayi S, et al. Influenza and

517 malaria coinfection among young children in western Kenya, 2009-2011. *J Infect Dis* [Internet].
518 2012 Dec 1 [cited 2022 Jul 7];206(11):1674–84. Available from:
519 <https://pubmed.ncbi.nlm.nih.gov/22984118/>

520 46. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita
521 M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-
522 19: a retrospective cohort study. *Clin Microbiol Infect* [Internet]. 2021 Jan 1 [cited 2022 Jul
523 4];27(1):83–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/32745596/>

524 47. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence
525 and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A
526 systematic review and metaanalysis. *PLoS One*. 2021 May 1;16(5 May).

527 48. Feldman C, Anderson R. The role of co-infections and secondary infections in patients with
528 COVID-19. *Pneumonia* [Internet]. 2021 [cited 2022 Jul 7]; Available from:
529 <https://doi.org/10.1186/s41479-021-00083-w>

530 49. Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-19
531 co-infection: a systematic review and meta-analysis. *AIDS Res Ther*. 2022 Dec 1;19(1).

532

533 **10 Supplementary Material**

534 Supplementary figures 1 to 3.

535 Supplementary tables 1 to 4

536 Supplementary references

537 **11 Data Availability Statement**

538 The datasets generated for this study can be found in the European Nucleotide Archive (ENA) database
539 (<https://www.ebi.ac.uk/ena/browser/home>) with project ID PRJEB55393 and sample IDs
540 SAMEA110648965-SAMEA110648977.

541

542 **Figure captions**

543 **Figure 1. (A)** Prevalence of SARS-CoV-2, malaria and co-infection by age group. **(B)** Venn diagram
544 representation of positive cases.

545 **Figure 2.** Phylogenetic tree with the 13 new SARS-CoV-2 Burkina Faso genomes placed on a
546 reference tree of 2022 published sequences from all over the world along with the diversity panel
547 below, a bar-chart showing the variation (i.e. mutations) of the 13 sequences in the genome relative to
548 the reference sequence Wuhan-Hu-1/2019 (MN908947). Phylogenetic tree generated with Nextclade
549 online software v2.5.0 (<https://clades.nextstrain.org>) (accessed on 13 September 2022) and visualized
550 using Auspice v2.37.3 (<https://auspice.us/>) (accessed on 13 September 2022).

551

552 **Table 1.** Distribution of positive cases by age classes and gender

SARS-CoV-2 and malaria co-infection Burkina

Age group	Sex	non-infected	COVID-19 IgG/A/M	malaria	COVID-19 Ig & malaria	SARS-CoV-2 PCR	SARS-CoV-2 PCR & COVID-19 Ig	SARS-CoV-2 PCR & malaria	Total
A 5-12	F	75	0	46	0	0	0	0	121
A 5-12	M	67	6	60	3	1	0	1	130
B 13-20	F	84	6	34	2	0	0	0	122
B 13-20	M	82	1	43	1	3	0	1	127
C 21-40	F	150	1	11	0	4	0	0	166
C 21-40	M	79	1	4	0	1	0	0	85
D >40	F	116	10	14	2	5	3	0	140
D >40	M	87	7	7	0	10	4	0	107
Sub-total	F	425	17	105	4	9	3	0	549
Sub-total	M	315	15	114	4	15	4	2	449
Total		740	32	219	8	24	7	2	998

553


554 **Table 2.** Circulating lineages and clades of SARS-CoV-2 in Burkina Faso from August to November
 555 2020. Mutations (aminoacid substitutions) relative to the reference sequence Wuhan-Hu-1/2019
 556 (MN908947) are showed.

Sample Accession (ENA)	Sample Alias	Lineage (Pangolin)	Clade (Nextstrain)	Global mutations	Spike mutations
SAMEA110648965	BOB20	A.21	19B	15	D614N, V622F, Q675R
SAMEA110648966	BOB49	A.19	19B	11	D614G
SAMEA110648967	BOB86	A.19	19B	3	D614G
SAMEA110648968	BOB108	A.19	19B	7	D614G
SAMEA110648969	BOB113	B.1.1.404	20B	7	D614G, G1219V
SAMEA110648970	BOB155	A.21	19B	7	-
SAMEA110648971	BOB159	B.1.1.404	20B	6	D614G
SAMEA110648972	BOB216	B.1.1.404	20B	7	D614G
SAMEA110648973	BOB323	B.1	20A	13	D614G
SAMEA110648974	BOB327	B.1.1.404	20B	8	Y248S, D614G
SAMEA110648975	DAN86	A.19	19B	7	D614G
SAMEA110648976	KOK14	B.1.1.118	20B	9	D614G, S640F
SAMEA110648977	ZAN2	A.21	19B	15	D614N, V622F


557

558

A.



B.



Nextclade Pango Lineage

